SNPMiner Trials by Shray Alag


SNPMiner SNPMiner Trials (Home Page)


Report for Clinical Trial NCT00752076

Developed by Shray Alag, 2020.
SNP Clinical Trial Gene

Detection of Epithelial Growth Factor Receptor (EGFR) Mutation in Malignant Pleural Effusion of Lung Cancer Patients and Cancer Cell Lines Establishment

1. Detection EGFR mutation of cancer cells from malignant pleural effusion. 2. Established the cancer cell lines with without EGFR mutation from malignant pleural effusion.

NCT00752076 NSCLC
MeSH: Pleural Effusion, Malignant Pleural Effusion
HPO: Pleural effusion

1 Interventions

Name: cancer cell lines establishment

Description: Detection of epithelial growth factor receptor (EGFR) mutation in malignant pleural effusion of lung cancer patients and cancer cell lines establishment

Type: Other

1


Primary Outcomes

Measure: EGFR mutation in malignant pleural effusion of lung cancer patients cancer cell lines establishment

Time: 1 year

Purpose: Basic Science

Single Group Assignment


There is one SNP

SNPs


1 L858R

In-frame deletions in exon 19 centered on codons 756 to 750 make up 45~50% of mutations, and another 35~45% consist of the missense mutation leucine to arginine at codon 858 (L858R) in exon 21 (8, 9, 10). --- L858R ---

It is interesting that exon 19 deletion have increased response and survival with TKIs compared with L858R cases (10, 13, 14). --- L858R ---

This is in contrast to the natural history of patients, where those with exon 19 deletions appear to have shorter survival than those with L858R (8). --- L858R ---



HPO Nodes


HPO:
Pleural effusion
Genes 64
LBR HLA-DRB1 TLR4 IGH MYD88 STAT4 CCR1 TAPT1 LACC1 PRSS2 HFE TSC1 BMP2 CCBE1 FSHR TSC2 PLVAP BCL2 HLA-DRB1 PIEZO1 CFI ERAP1 CFTR C1QA TCF4 KIF11 TSC2 SPINK1 CD46 KLRC4 IL10 UBAC2 HLA-B MIF C1R CBL ADAMTS3 C4A STAT4 INHBA IL12A-AS1 IL12A IL23R TSC1 IRAK1 PRSS1 BCL6 DNASE1L3 MST1 IL6 BTNL2 CCND1 HLA-DRB1 CCBE1 MEFV SPP1 HELLPAR SOX18 CFH CTRC FAS GPR35 RIT1 FAT4